Association Between SLC25A48 Expression and Chronic Obstructive Pulmonary Disease Progression
Trial Snapshot
- Phase
- Not Applicable
- Status
- Recruiting
- Sponsor
- Fu Jen Catholic University
- Enrollment
- 180
- Locations
- 2
- Primary Endpoint
- expression of SLC25A48
Study Overview
Brief Summary
This study aims to investigate the expression level of SLC25A48, a mitochondrial choline transporter, in peripheral blood mononuclear cells of patients with chronic obstructive pulmonary disease, and to analyze its correlation with inflammatory markers and choline metabolic byproducts.
Detailed Description
Background:
Chronic obstructive pulmonary disease is the third leading cause of death worldwide, characterized by airflow limitation, alveolar damage, and chronic systemic inflammation. These features are closely associated with malnutrition, muscle loss, and oxidative stress. Mitochondrial dysfunction plays a critical role in immune dysregulation, with peripheral blood mononuclear cells widely used in studies on inflammation and metabolism. Choline, essential for one-carbon metabolism and immune function, requires specific transporters to enter mitochondria. SLC25A48, a newly identified mitochondrial choline transporter, is linked to impaired choline uptake, elevated reactive oxygen species, and metabolic imbalance. However, its role in chronic obstructive pulmonary disease remains unclear.
Study Design:
This multicenter, prospective observational study
Methods:
Study Design
- Study Type
- Observational
- Observational Model
- Case Control
- Time Perspective
- Prospective
Eligibility Criteria
- Ages
- 18 Years to — (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- Yes
Inclusion Criteria
- •pre-COPD or COPD stages I-IV as per the 2023 GOLD guidelines (case group)
- •healthy individuals without chronic diseases or major medical conditions
Exclusion Criteria
- •diagnosed with neuromuscular diseases
- •experienced respiratory disease exacerbation requiring emergency care or hospitalization in the past three months
- •assessed by a physician to have severe malnutrition or a significantly low BMI
- •continuously taking folic acid supplements
- •willing to receive or have already received self-paid nutrition clinic services at this hospital
Arms & Interventions
Control group
healthy controls
Case group
Pre-COPD or COPD stages I-IV as per the 2023 GOLD guidelines
Outcomes
Primary Outcomes
expression of SLC25A48
Time Frame: one day
the expression level of SLC25A48 in mitochondria isolated from peripheral blood mononuclear cells
Secondary Outcomes
No secondary outcomes reported
Investigators
Ke-Yun, Chao
Assistant Professor
Fu Jen Catholic University